Comparative Pharmacology
Head-to-head clinical analysis: LODINE XL versus VIVLODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE XL versus VIVLODEX.
LODINE XL vs VIVLODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis leading to anti-inflammatory, analgesic, and antipyretic effects.
COX-2 inhibitor; reduces prostaglandin synthesis via inhibition of cyclooxygenase-2 (COX-2) with minimal COX-1 inhibition.
400 mg or 600 mg orally once daily.
Once daily oral administration of 100 mg or 200 mg capsules. The recommended dose is 100 mg once daily; dose may be increased to 200 mg once daily if response is inadequate. Maximum daily dose: 200 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 hours. Steady-state is achieved within 2 days.
Terminal elimination half-life of the active moiety meloxicam is approximately 20 hours (range 12-24 h), allowing once-daily dosing in chronic pain.
Renal excretion of metabolites accounts for approximately 70% of a dose; fecal excretion accounts for about 20%.
VIVLODEX is a meloxicam NSAID prodrug. Following hydrolysis to meloxicam, excretion is primarily hepatic (metabolism) and renal (urine). Approximately 50% of meloxicam dose is excreted in urine as metabolites and <5% as parent drug; about 40% in feces. Biliary excretion is minor.
Category C
Category C
NSAID
NSAID